Stryker Return on Tangible Equity 2010-2025 | SYK
Current and historical return on tangible equity values for Stryker (SYK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Stryker Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $2.86B | $-4.29B | -224.10% |
| 2024-12-31 | $2.99B | $0.38B | -798.13% |
| 2024-09-30 | $3.59B | $-1.19B | -459.23% |
| 2024-06-30 | $3.45B | $-0.01B | -353.28% |
| 2024-03-31 | $3.36B | $-0.69B | -202.99% |
| 2023-12-31 | $3.17B | $-1.24B | -146.05% |
| 2023-09-30 | $2.59B | $-1.96B | -97.79% |
| 2023-06-30 | $2.71B | $-2.73B | -88.87% |
| 2023-03-31 | $2.63B | $-2.73B | -74.26% |
| 2022-12-31 | $2.36B | $-3.15B | -55.38% |
| 2022-09-30 | $2.46B | $-3.58B | -58.63% |
| 2022-06-30 | $2.08B | $-4.69B | -49.06% |
| 2022-03-31 | $2.02B | $-5.61B | -48.82% |
| 2021-12-31 | $1.99B | $-2.88B | -51.21% |
| 2021-09-30 | $1.90B | $-3.77B | -42.36% |
| 2021-06-30 | $2.08B | $-4.24B | -58.56% |
| 2021-03-31 | $1.41B | $-4.68B | -54.58% |
| 2020-12-31 | $1.60B | $-5.25B | -113.08% |
| 2020-09-30 | $1.76B | $-0.06B | -783.05% |
| 2020-06-30 | $1.60B | $-0.33B | -499.14% |
| 2020-03-31 | $2.16B | $-0.02B | -442.99% |
| 2019-12-31 | $2.08B | $-0.49B | -260.86% |
| 2019-09-30 | $3.43B | $-0.45B | -370.28% |
| 2019-06-30 | $3.55B | $-1.00B | -316.05% |
| 2019-03-31 | $3.52B | $-1.26B | -269.21% |
| 2018-12-31 | $3.55B | $-1.00B | -230.53% |
| 2018-09-30 | $1.24B | $-1.24B | -84.74% |
| 2018-06-30 | $1.08B | $-1.74B | -92.54% |
| 2018-03-31 | $1.02B | $-2.19B | -148.60% |
| 2017-12-31 | $1.02B | $-0.67B | -592.16% |
| 2017-09-30 | $1.78B | $-0.07B | -2105.33% |
| 2017-06-30 | $1.70B | $0.18B | -667.98% |
| 2017-03-31 | $1.69B | $-0.14B | -306.81% |
| 2016-12-31 | $1.65B | $-0.31B | 827.64% |
| 2016-09-30 | $1.66B | $-0.75B | 179.79% |
| 2016-06-30 | $1.61B | $-1.00B | 92.98% |
| 2016-03-31 | $1.62B | $2.86B | 62.42% |
| 2015-12-31 | $1.44B | $2.58B | 58.97% |
| 2015-09-30 | $1.18B | $2.46B | 49.19% |
| 2015-06-30 | $0.93B | $2.46B | 39.84% |
| 2015-03-31 | $0.67B | $2.26B | 27.52% |
| 2014-12-31 | $0.52B | $2.39B | 19.73% |
| 2014-09-30 | $0.64B | $2.26B | 22.76% |
| 2014-06-30 | $0.69B | $2.81B | 20.20% |
| 2014-03-31 | $0.77B | $2.98B | 20.22% |
| 2013-12-31 | $1.01B | $3.21B | 24.19% |
| 2013-09-30 | $0.89B | $4.60B | 19.29% |
| 2013-06-30 | $1.14B | $4.49B | 24.23% |
| 2013-03-31 | $1.25B | $4.34B | 26.48% |
| 2012-12-31 | $1.30B | $5.03B | 27.21% |
| 2012-09-30 | $1.43B | $4.96B | 31.38% |
| 2012-06-30 | $1.40B | $4.58B | 32.40% |
| 2012-03-31 | $1.39B | $4.52B | 32.47% |
| 2011-12-31 | $1.35B | $4.17B | 31.89% |
| 2011-09-30 | $1.24B | $4.06B | 27.38% |
| 2011-06-30 | $1.25B | $4.35B | 25.31% |
| 2011-03-31 | $1.26B | $4.29B | 24.49% |
| 2010-12-31 | $1.27B | $5.40B | 23.89% |
| 2010-09-30 | $1.28B | $5.70B | 24.55% |
| 2010-06-30 | $1.18B | $5.16B | 22.72% |
| 2010-03-31 | $1.15B | $5.05B | 22.23% |
| 2009-12-31 | $1.11B | $5.00B | 21.79% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $146.527B | $22.595B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.407B | 27.95 |
| Boston Scientific (BSX) | United States | $151.037B | 37.81 |
| EssilorLuxottica (ESLOY) | France | $129.703B | 0.00 |
| Medtronic (MDT) | Ireland | $112.146B | 15.90 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.313B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.844B | 28.38 |
| ResMed (RMD) | United States | $36.979B | 27.78 |
| Agilent Technologies (A) | United States | $32.895B | 21.44 |
| GE HealthCare Technologies (GEHC) | United States | $32.794B | 15.57 |
| Terumo (TRUMY) | Japan | $26.561B | 34.50 |
| Koninklijke Philips (PHG) | Netherlands | $22.051B | 15.85 |
| Insulet (PODD) | United States | $21.941B | 86.12 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.277B | 11.74 |
| Baxter (BAX) | United States | $15.529B | 11.59 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.253B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.430B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $5.971B | 20.78 |
| Lantheus Holdings (LNTH) | United States | $5.642B | 14.23 |
| Prestige Consumer Healthcare (PBH) | United States | $4.203B | 18.78 |
| Perrigo (PRGO) | Ireland | $3.596B | 9.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.385B | 15.42 |
| ICU Medical (ICUI) | United States | $3.275B | 24.15 |
| Envista Holdings (NVST) | United States | $3.174B | 26.38 |
| GN Store Nord (GNNDY) | Denmark | $2.180B | 18.06 |
| QuidelOrtho (QDEL) | United States | $1.997B | 13.73 |
| LeMaitre Vascular (LMAT) | United States | $1.901B | 42.49 |
| AtriCure (ATRC) | United States | $1.730B | 0.00 |
| Acuren (TIC) | United States | $1.271B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.201B | 12.19 |
| Neogen (NEOG) | United States | $1.131B | 14.47 |
| BioLife Solutions (BLFS) | United States | $1.126B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.100B | 24.74 |
| Kestra Medical Technologies (KMTS) | United States | $1.063B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.976B | 12.48 |
| InMode (INMD) | Israel | $0.895B | 9.02 |
| Capricor Therapeutics (CAPR) | United States | $0.650B | 0.00 |
| Evolus (EOLS) | United States | $0.647B | 0.00 |
| CeriBell (CBLL) | United States | $0.647B | 0.00 |
| Owens & Minor (OMI) | United States | $0.619B | 5.13 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.609B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.584B | 0.00 |
| Valneva SE (VALN) | France | $0.515B | 0.00 |
| Surmodics (SRDX) | United States | $0.420B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.408B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.347B | 12.76 |
| SNDL (SNDL) | Canada | $0.347B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.322B | 57.20 |
| Canopy Growth (CGC) | Canada | $0.313B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.289B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.40 |
| Cresco Labs (CRLBF) | United States | $0.265B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 11.87 |
| Sanuwave Health (SNWV) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.221B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.216B | 0.00 |
| Biote (BTMD) | United States | $0.210B | 5.89 |
| Quanterix (QTRX) | United States | $0.209B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.204B | 0.00 |
| Brainsway (BWAY) | Israel | $0.197B | 52.25 |
| High Tide (HITI) | Canada | $0.193B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.86 |
| Organigram Global (OGI) | Canada | $0.181B | 0.00 |
| Exagen (XGN) | United States | $0.154B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.139B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 16.54 |
| Jin Medical (ZJYL) | China | $0.120B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.091B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.59 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.082B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.066B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.058B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.14 |
| Nephros (NEPH) | United States | $0.036B | 48.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |